Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #2: Drugs (in this case IC.

Slides:



Advertisements
Similar presentations
© CM Gibson 2006 Cross-sections of left ventricle after experimental coronary artery occlusion Cross-sections of left ventricle after experimental coronary.
Advertisements

Unstable Angina: Embolism Can Occur Prior to PCI Thrombus in proximal RCA Stain of muscle before injection begins: TIMI Myocardial perfusion grade 1 CM.
PBL CV 2 Pathophysiology of coronary artery disease.
Regional AMI Care: Bridging the Rural Health Care Gap Darren B. Bean, MD University of Wisconsin Emergency Medicine/Medflight Director UW Level 1 Heart.
Radial versus Femoral Randomized Investigation in ST Elevation Acute Coronary Syndrome the RIFLE STEACS study Enrico Romagnoli, MD PhD Principal investigators:
Intracoronary Serotonin and Endothelin Release After PCI / Stenting Taylor AJ. Am Heart J Aug;148(2): e10 Leosco et al, AJC 1999;84:
Beta Blockade and the Heart John Hakim, M.D Cardiology Fellow West Virginia University Division of Cardiology.
Time Is Myocardium and the Wavefront of Necrosis CM Gibson 2002.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
GP IIb/IIIa Inhibition in STEMI: Growing Clinical Trial Evidence.
Clinical Trial Results. org C. Michael Gibson, M.S., M.D. Director TIMI Data Coordinating Center Invasive Cardiologist Beth Israel Deaconess Medical Center.
Enhancement of thrombolysis in AMI is an unmet clinical need Increase the rate of reperfusion without increasing bleeding Reduce the time to complete reperfusion.
Is PCI necessary for AMI related artery with TIMI 3 flow ? Donghoon Choi Yonsei Cardiovascular Center Yonsei University College of Medicine.
Primary Angioplasty and Hemodynamic Support in Cardiogenic Shock Department of Internal Medicine, College of Medicine, Yonsei University Hyuck Moon Kwon,
Angiographic Estimates of Myocardium at Risk During Acute Myocardial Infarction: a Validation Study Using Cardiac MRI José T. Ortiz, Sheridan N. Meyers,
TREATMENT OF ACUTE MYOCARDIAL INFARCTION NUR 351/352 PROFESSOR DIANE E. WHITE RN MS CCRN.
Improving outcome of STEMI PCI: Preliminary Results of Crystal AMI trial Rajesh M. Dave, MD Principal investigator on behalf of Crystal AMI Investigators.
Beyond TIMI 3 Flow CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital.
The “Code White” Team of Dr. William Ganz: 1979 Goal of IC SK Before PCI: Get the artery open.
TIMI 14 Antman et al. Circ 99: 2720,1999 Phases of Trial ControlInvestigational Accel tPA Accel tPA Accel tPA rPA ( U) rPA ( U) No lytic Abx.
The 90 Minute Wall: 60% Rates of TIMI Grade 3 Flow % TIMI 3 Flow.
Pathophysiology of the coronary circulation: role of FFR Giuseppe Biondi Zoccai University of Modena and Reggio Emilia, Modena, Italy
TACTICS- TIMI 18 Treat Angina with Aggrastat TM and Determine Cost of Therapy with an Invasive or Conservative Strategy.
TIMI 10A Protocol Design TNK- tPA Bolus ASA + IV Heparin (APTT 55-85) Follow-up Hosp. Discharge to 30 days Pt. with Acute MI < 12h End Points: Pharmacokinetics.
LESSON 1 LESSON 1 Establishment of:
Diagnosis of acute MI Pharmacologic therapy* Immediate angiography PTCAPTCA Other Rx *Antithrombin agents, antiplatelet agents, and fibrinolytic agents.
New strategies and perfusion/aspiration devices for primary PCI Sandra Garcia Cruset, PhD. Cordynamic B.U. Marketing Manager.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
PROTECT: What Have We Learned Lesson 2: TMPG is associated with clinical and biomarker outcomes following PCI.
Annual Patient Admissions for Acute Coronary Syndromes 1.4 MM Non-ST elevation ACS 0.6 MM ST-elevation MI ~ 2.0 MM patients admitted to CCU or telemetry.
High-risk ST elevation MI patients (>4 mm elevation), Sx < 12 hrs 5 PCI centers (n=443) and 22 referring hospitals (n=1,129), transfer in < 3 hrs High-risk.
Heart Alert Quandary Kiran K. Cheruku, MD Interventional Cardiologist Heart And Vascular Institute of Texas.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: A guide to therapeutic decision-making in patients.
SPEED : GUSTO-IV PILOT GUSTO-IV Pilot Trial. SPEED : GUSTO-IV PILOT Rationale for Combination Therapy in AMI Enhance Incidence and Speed of Reperfusion.
Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic.
Randomized Early versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial) Mauro Maioli, MD, Francesco.
Rationale for the Clinical Evaluation of Combination GP IIb-IIIa Inhibitor and Low-Dose Fibrinolytic Therapy in ST-Elevation Myocardial Infarction.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Phasic coronary blood flow velocity pattern and.
Circ Res.2003;93:e98-e103 R2 이홍주. HMG-CoA reductase inhibitors (statins) - beneficial therapeutic effects in patients at risk for cardiovascular events.
Total Occlusion Study of Canada (TOSCA-2) Trial
CRT 2015 Unmet Needs in STEMI Interventions
Percutaneous Coronary Interventions for Patients with Relative Contra-indications: Severely Depressed Left Ventricular Function Great Wall International.
Vilnius University Hospital Santariskiu Clinics
Intra Coronary AdjunctivE Tenecteplase During Primary PCI for STEMI:
Fractional Flow Reserve Workshop
Andrew McNeice1,2, Imad J. Nadra1,2, Simon D
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
PROTECT – TIMI 30 Trial Randomized Trial to Evaluate the Relative PROTECTion against Post-PCI Microvascular Dysfunction and Post-PCI Ischemia among Anti-Platelet.
Randomized Comparison in the Setting of Acute MI
ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.
In STEMI Complete Reperfusion (TFG 3, TMPG 3, ST Res  70%) is Associated with a Greater Percent of Receptors Occupied by Integrilin 52.0% % Pts With Complete.
Myocardial Staining (TMPG 1)  Post-Stent in AMI
52.0% Complete Resolution TFG 3 TMPG 3 ST Resolution  70% p=0.006
Emerging Data Regarding the Potential Benefits of Early Initiation of Clopidogrel Among ACS Patients C. Michael Gibson, M.S., M.D.
(p < 0.05 for paclitaxel angioplasty vs. either control)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
A New Angiographic Risk Score in Facilitated PCI
Dye strongly persistent
Association of Troponin Elevation with Risk of Mortality in Acute Coronary Syndromes Mortality at 42 Days  % A study by Antman and.
European Heart Journal Advance Access
Evolution of Myocardial Blush after MI
GUSTO 1 Trial 41,000 patients enrolled, landmark study
Result of coronary angiogram among patients with and without diabetes admitted with first-time acute coronary syndrome (a significant stenosis was defined.
ESPRIT INTEGRITI TACTICS Rate of Increase in DSA
Dye strongly persistent
Presentation transcript:

Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #1: Occluded Arteries Cause Acute MI Proof of Concept #2: Drugs (in this case IC SK) Recanalize Occluded Arteries Proof of Concept #2: Drugs (in this case IC SK) Recanalize Occluded Arteries The “Code White” Team of Dr. William Ganz: 1979

Results of the NIH Sponsored TIMI 1 Trial % Arteries Opened Documented to be Closed % Arteries Opened Documented to be Closed % All Arteries Open at 90 Min. % All Arteries Open at 90 Min. % of Patients Cheesboro et al, Circulation 1987;76: DSMB stopped trial early; felt that greater rate of patency would necessarily translate into improved outcomes

The Dark Days of the Open Artery Hypothesis: Results of Early Megatrials The Dark Days of the Open Artery Hypothesis: Results of Early Megatrials Despite the fact that TIMI 1 showed superior patency for tPA over SK, early megatrials showed no difference in mortality Early megatrials used 3 hour dosing of tPA (not front-loaded) and late SQ heparin (not early IV heparin) Despite the fact that TIMI 1 showed superior patency for tPA over SK, early megatrials showed no difference in mortality Early megatrials used 3 hour dosing of tPA (not front-loaded) and late SQ heparin (not early IV heparin)

Occlusion Penetration Slow Flow Normal Flow TIMI 0 TIMI 1 TIMI 2 TIMI 3 % Mortality 9.3% 6.1% 3.7% p< vs TIMI 0/1 p< vs TIMI 2 p< vs TIMI 0/1 p< vs TIMI 2 P=0.003 vs TIMI 0/1 Team 2 German GUSTO 1 TAM I 1-7 TIM I 1,4 5,10B TIM I 1,4 5,10B TIM I 1,4 5,10B TIM I 1,4 5,10B TIM I 1,4 5,10B TIM I 1,4 5,10B CM Gibson 1998 in Acute Coronary Syndromes Sample Size of Pooled Analysis: 5, Restoration of “Normal” Epicardial Flow Yields Better Outcomes Unfortunately rate of agreement only 71%

LAD Frame 1: Dye Touches Both Borders & Moves Forward Frame 0: Dye Touches One or No Borders Last Frame Definition Frame 21: Dye first enters landmark First Frame Definition RCA LCX Distal Landmark Normal Flow in the Absence of MI : frames 1st branch off posterolateral Last branch off most distal OM “Whale’s tail” or “pitchfork” or most distal branch LAD at apex Gibson, Circulation 1996; 93:

Even Faster Epicardial Coronary Blood Flow is Better CTFC < 14 CTFC > % (n=41) (n = 18/640) (n =35/563) 2.8% p= “TIMI 4” Flow TIMI 3 Flow 14 < CTFC < % % Risk of In Hospital Mortality Gibson, Circulation 1999; 99: Hyperemic Flow Reproducibility: r = 0.97 between readers Accuracy: r=0.88 vs Doppler velocity Reproducibility: r = 0.97 between readers Accuracy: r=0.88 vs Doppler velocity

Percent Stenosis 67.8% Percent Stenosis 67.8% Percent Stenosis 69.5% Percent Stenosis 69.5% Percent Stenosis 67.1% Percent Stenosis 67.1% Distal to Stenosis: 11.8 cm or 76.6% Distal to Stenosis: 9.2 cm or 70.1% Distal to Stenosis: 7.8 cm or 59.8% Diameter: 2.97 mm Diameter: 3.10 mm Diameter: 3.23 mm SBP mmHg SBP mmHg SBP mmHg SBP mmHg SBP mmHg SBP mmHg Wedge Pressure: 18.0 mm Hg Wedge Pressure: 16.4 mm Hg Wedge Pressure: 19.7 mm Hg N = 1,044 N = 264 N = 778 RCA: 90 Min. TIMI 3 Flow: 64.2% Composes 2/3 rds of TIMI 3 flow 90 Min. CTFC: 33.4 Post PTCA CTFC 25.5 Thin walled RV Low filling pressures RCA: 90 Min. TIMI 3 Flow: 64.2% Composes 2/3 rds of TIMI 3 flow 90 Min. CTFC: 33.4 Post PTCA CTFC 25.5 Thin walled RV Low filling pressures LCX: 90 Min. TIMI 3 Flow: 56.4% 90 Min. CTFC: 40.4 Post PTCA CTFC 36.5 Thick walled LV High filling pressures LCX: 90 Min. TIMI 3 Flow: 56.4% 90 Min. CTFC: 40.4 Post PTCA CTFC 36.5 Thick walled LV High filling pressures LAD: 90 Min. TIMI 3 Flow: 46.0% Composes 2/3rds of TIMI 2 flow 90 Min. CTFC: 39.1 Post PTCA CTFC 30.0 Thick walled LV High filling pressures LAD: 90 Min. TIMI 3 Flow: 46.0% Composes 2/3rds of TIMI 2 flow 90 Min. CTFC: 39.1 Post PTCA CTFC 30.0 Thick walled LV High filling pressures Differences Among the Three Epicardial Arteries Following Thrombolytic Administration in 2,068 TIMI Patients Differences Among the Three Epicardial Arteries Following Thrombolytic Administration in 2,068 TIMI Patients CM Gibson J Am Coll Cardiol 1999; 34: